Teva Pharmaceutical Industries Limited Announces FDA Approval of Generic TOBI® in the United States

JERUSALEM--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announces today that the U.S. Food and Drug Administration has granted approval of the generic equivalent to TOBI® (Tobramycin Inhalation Solution USP) in the United States. Pursuant to an agreement with Novartis on this product, Teva expects to launch this product in late November. Marketed by Novartis, TOBI® had annual sales of approximately $350 million in the United States, according to IMS data as of June 30, 2013.

Help employers find you! Check out all the jobs and post your resume.